87269-97-4
Chemical Structure
Ramiprilat
Synonym(s): HOE 498 diacid; Ramipril diacid
- CAS No.: 87269-97-4
- Formula:C21H28N2O5
- Molecular Weight:388.46
IUPAC Name: (2S,3aS,6aS)-1-(((S)-1-carboxy-3-phenylpropyl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid
InChIKey: KEDYTOTWMPBSLG-HILJTLORSA-N
SMILES: O=C([C@@H]1C[C@@](CCC2)([H])[C@@]2([H])N1C([C@@H](N[C@H](C(O)=O)CCC3=CC=CC=C3)C)=O)O
Biological Activity: Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat has acute antlhypertensive effect. Ramiprilat can be used for high blood pressure and heart failure research[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ramiprilat | 97.09% | Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat has acute antlhypertensive effect. Ramiprilat can be used for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramiprilat (Standard) | 96.61% | Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramiprilat-d4 hydrochloride | Ramiprilat-d4 hydrochloride is deuterated labeled Ramiprilat (HY-A0115). Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramiprilat-d5 (Mixture of Diastereomers) | Ramiprilat-d5 (Mixture of Diastereomers) is the deuterium labeled Ramiprilat (Mixture of Diastereomers). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramiprilat-d5 | 98.33% | Ramiprilat-d5 is deuterium labeled Ramiprilat. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ramiprilat-d3 (Mixture of Diastereomers) | Ramiprilat-d3 (Mixture of Diastereomers) is the deuterium labeled Ramiprilat (Mixture of Diastereomers). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research[1]. [Content Brief]
- [2]. Wiemer G, et al. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991 Oct;18(4):558-63. [Content Brief]
- [3]. Wall TM, et al. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism. Eur J Pharmacol. 1996 Jun 13;306(1-3):165-74. [Content Brief]
- [4]. Serrano-Rodríguez JM, et al. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. Vet J. 2016 Feb;208:38-43. [Content Brief]
- [5]. Cachofeiro V, et al. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992 Feb;19(2):138-45. [Content Brief]